Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karina J Yoon

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Pharmacological Research|March 6, 2020
Developing effective combination therapy for pancreatic cancer: An overviewAubrey L Miller, Patrick L Garcia, Karina J Yoon
Cancers|May 28, 2020
Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of ModelsPatrick L Garcia, Aubrey L Miller, Karina J Yoon
Cancer Drug Resistance (Alhambra, Calif.)|January 1, 2020
Sphingolipid metabolism and drug resistance in ovarian cancerKelly M Kreitzburg, Robert C A M van Waardenburg, Karina J Yoon
Cancer Letters|October 13, 2019
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinomaSamuel C Fehling, Aubrey L Miller, Patrick L Garcia, et al.
Cancer Drug Resistance (Alhambra, Calif.)|October 19, 2020
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinomaAubrey L Miller, Patrick L Garcia, Tracy L Gamblin, et al.
BMC Cancer|May 30, 2013
N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cellsJoseph M Feduska, Patrick L Garcia, Stephanie B Brennan, et al.
Oncotarget|November 29, 2016
Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxinSelma M Cuya, Evan Q Comeaux, Keith Wanzeck, et al.
Cancer Drug Resistance (Alhambra, Calif.)|November 13, 2024
The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer modelsAubrey L Miller, Patrick L Garcia, Rebecca B Vance, et al.
Frontiers in Oncology|July 7, 2022
The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer CellsPatrick L Garcia, Aubrey L Miller, Ling Zeng, et al.
Translational Oncology|November 10, 2018
Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in HepatoblastomaLaura L Stafman, Adele P Williams, Evan F Garner, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Pharmacological Research|March 6, 2020
Developing effective combination therapy for pancreatic cancer: An overviewAubrey L Miller, Patrick L Garcia, Karina J Yoon
Cancers|May 28, 2020
Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of ModelsPatrick L Garcia, Aubrey L Miller, Karina J Yoon
Cancer Drug Resistance (Alhambra, Calif.)|January 1, 2020
Sphingolipid metabolism and drug resistance in ovarian cancerKelly M Kreitzburg, Robert C A M van Waardenburg, Karina J Yoon
Cancer Letters|October 13, 2019
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinomaSamuel C Fehling, Aubrey L Miller, Patrick L Garcia, et al.
Cancer Drug Resistance (Alhambra, Calif.)|October 19, 2020
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinomaAubrey L Miller, Patrick L Garcia, Tracy L Gamblin, et al.
BMC Cancer|May 30, 2013
N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cellsJoseph M Feduska, Patrick L Garcia, Stephanie B Brennan, et al.
Oncotarget|November 29, 2016
Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxinSelma M Cuya, Evan Q Comeaux, Keith Wanzeck, et al.
Cancer Drug Resistance (Alhambra, Calif.)|November 13, 2024
The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer modelsAubrey L Miller, Patrick L Garcia, Rebecca B Vance, et al.
Frontiers in Oncology|July 7, 2022
The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer CellsPatrick L Garcia, Aubrey L Miller, Ling Zeng, et al.
Translational Oncology|November 10, 2018
Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in HepatoblastomaLaura L Stafman, Adele P Williams, Evan F Garner, et al.
Pageof 5